Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1902MR)

This product GTTS-WQ1902MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1902MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12065MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ13989MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10159MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ11872MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ15968MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ11179MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ8333MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ10560MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY­3074828
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW